Navigation Links
Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
Date:11/10/2011

LEXINGTON, Mass., Nov. 10, 2011 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company completed its first close of $2.2 million of a Series A angel-led financing. Cherrystone Angels of Providence, Rhode Island led the round, with participation from Boston Harbor Angels and other undisclosed individuals. Mr. Robert Manning, the co-Chairman of Cherrystone Angels, will join the Avaxia board. Mr. Manning has served as a senior executive at Citigroup and on a number of early-stage company boards, including SmartCells.

Dr. Barbara Fox, Avaxia's founder and CEO, commented, "This investment will allow us to aggressively pursue the development of our AVX-470 anti-TNF oral antibody and prepare Avaxia to initiate a clinical trial in inflammatory bowel disease next fall. When coupled with the funding we have received from BARDA (Biomedical Advanced Research and Development Authority) to develop AVX-470 for GI Acute Radiation Syndrome, our investors have a unique opportunity to participate in the rapid creation of value in two important disease areas. We are in advanced discussions with a limited number of other qualified investors as we work to complete this planned round of financing. The angel community's response to Avaxia has been very gratifying."

The funds from this financing will be used to manufacture drug to be used in the clinical trial and to conduct final pre-clinical studies in advance of a Phase 1b clinical trial in patients with inflammatory bowel disease, being planned for the second half of 2012. The company has raised $4.3 million in non-dilutive financing prior to this equity round. In addition to a loan from the Massachusetts Life Sciences Center and several SBIR grants, the company was awarded a $2.9 million, 2-year contract with BARDA that fully funds the initi
'/>"/>

SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
2. Dr. Lester Mandelker to Collaborate with Nuovo Biologics, LLC
3. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
4. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
5. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
6. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
7. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
8. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
9. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
10. Creabilis Raises €15M ($20M) in Series B Fundraising Round
11. SironRX Therapeutics Raises $3.4 Million Series A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 26 Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA.OB) ... information is available via Standard & Poor,s,Corporation Records ... full,description of Duska Therapeutics is published in the ... securities manual for secondary,trading in approximately 38 states ...
... in 21st ... ... in gene expression analysis-based diagnostics, is pleased to,announce that the company ... Dutch Innovation Platform.,MammaPrint, a 70-gene signature diagnostic test that predicts high ...
... FREMONT, Calif., June 26 ValGenesis, Inc., ... solutions, announced,the worldwide availability of ValGenesis 2.0, ... scalable validation life cycle,management and automation product., ... software suite can,efficiently manage the entire validation ...
Cached Biology Technology:Duska Therapeutics Obtains Standard & Poor's Listing 2Agendia's MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform 2Agendia's MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform 3ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0 2ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0 3
(Date:4/23/2014)... 23, 2014 A biomedical engineer at the University ... technology to make blood transfusions safer. His work is ... Institutes of Health (NIH). , Blood transfusions save ... modern medicine,s absolute necessities. Without them, for instance, routine ... are perfect, however. There,s strong evidence that transfusions of ...
(Date:4/23/2014)... leading a 2 million Food Standards Agency (FSA) project ... and industry workers. , Norovirus outbreaks can rapidly ... batch of frozen strawberries infected 11,000 people in Germany, ... of which strains cause infection and which foods are ... , Researchers will produce data that will help the ...
(Date:4/22/2014)... are all sorts of signaling strategies in nature. Peacocks ... satin bowbirds build specialized stick structures, called bowers, and ... bitterling males show off bright nuptial coloration during spawning ... communicate with others. , ... fitness implications for individuals that are either signaling or ...
Breaking Biology News(10 mins):UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Best practices in communication for the animal world 2Best practices in communication for the animal world 3
... been elected to Fellowship in the American Academy ... annually through a highly selective, peer-review process, based ... contributions that have advanced microbiology. There are now ... including basic and applied research, teaching, public health, ...
... underrepresented in the applicant pool for faculty positions in math, ... apply are interviewed and hired at rates equal to or ... the National Research Council. Similarly, women are underrepresented among ... tenure at the same or higher rates than men. ...
... KNOXVILLE -- As swine flu spread from Mexico to Texas ... began to alter their behavior. Families kept children home from ... of eating out. In so doing, the American population may ... How human behavior changes the spread of emerging infectious diseases, ...
Cached Biology News:Seventy-three scientists elected to the American Academy of Microbiology 2Seventy-three scientists elected to the American Academy of Microbiology 3Seventy-three scientists elected to the American Academy of Microbiology 4Women faring well in hiring process for science faculty jobs at research universities 2Women faring well in hiring process for science faculty jobs at research universities 3Women faring well in hiring process for science faculty jobs at research universities 4Scientists examine human behavior and the threat of disease 2
Purified anti-mouse Tim-1...
Biotin d anti-mouse Tim-1...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Request Info...
Biology Products: